According to the latest European Association for the Study of the Liver (EASL) practice guidelines, the first-line pharmacological treatment for HRS-AKI is terlipressin in combination with albumin (The European Association for the study of the Liver, 2018; Nanda et al., 2018); however, this vasopressin analog is not available in many countries, including the United States (Singh et al., 2012). Here, ALB is linked to acute kidney injury.